Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 15/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11313959 | 0.84 | SLC5A2 (0.55) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12110835 | 0.84 | TDP1 (0.56) | TSHRTDP1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL2707322 | 0.83 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2871442 | 0.83 | SLC5A2 (0.54) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27969548 | 0.82 | SLC5A2 (0.51) | SLC5A2SLC5A1SMN1; SMN2HPGDADRA2A | |
| SCHEMBL29455231 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL29386304 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL38150 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14608649 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1933786 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | disclosed |
| WO-2018029611-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| EP-3246324-A2 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USES THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2017-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885TSHR 3697/4885TDP1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.